Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or secondary ITP;~* Platelet count below surgical platelet count threshold (50 x10\^9/L for minor surgery; 100 x 10\^9/L for major surgery);~* 18 years of age or older;~* On stable doses of concomitant ITP medications (i.e the dose administered has not changed) or no ITP medication for at least 2 weeks;~* At least 3-weeks lead time available between randomization and scheduled surgery;~* IVIG and Eltrombopag are acceptable ITP treatment options for this patient;~* Able to provide informed consent.~Exclusion Criteria:~* Pregnancy or breastfeeding;~* Treatment with IVIG within the last 2 weeks;~* Treatment with a thrombopoietin receptor agonist (eltrombopag or romiplostim) within the last 4 weeks;~* AST, ALT above 2X upper limit of normal;~* Bilirubin above 1.5X upper limit of normal in the absence of clinically benign liver disorder (eg. Gilberts syndrome);~* Deep vein thrombosis, myocardial infarction, thrombotic stroke or arterial thrombosis in the last 12 months;~* History of bone marrow reticulin or fibrosis;~* Known liver cirrhosis;~* Active malignancy (defined as requiring treatment or palliation within the last 6 months);~* Any additional laboratory test result, health related illness or other diagnosis which, in the opinion of the treating physician, may put the subject's health or safety at risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
- IVIG infusion (Type: ACTIVE_COMPARATOR): Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.

Based on this trial design, predict the completion outcome and termination type (if applicable).